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Throughout Latin America, an epidemic of a kidney disease of an unknown etiology
has been occurring since the late 1990s, and this disease is being called
“Mesoamerican nephropathy.” Mesoamerican nephropathy predominantly affects
male sugarcane workers. In Chichigalpa, Chinandega, Nicaragua, there is sugarcane
plantation that is being heavily impacted by the Mesoamerican nephropathy
epidemic, and they invited researchers from Baylor College of Medicine to
investigate the epidemic. The prospective epidemic investigation began in 2015, and
it is an ongoing investigation. Based on the compilation of data collected during the
preliminary investigation, our hypothesis is that a possible zoonotic disease, such as
hantavirus and/or Leptospira, could be causing Mesoamerican Nephropathy due to
the large rodent population in the fields. Our specific aims were to determine the
prevalence of hantavirus and Leptospira among the study population and to describe
and evaluate the differences between potential risk factors for MeN. We tested for

IgM and IgG antibodies using ELISA kits for hantavirus and Leptospira. For
hantavirus, we tested 149 cases and 50 controls. Due to kit validation issues, we
tested 92 controls for Leptospira IgM and IgG antibodies, and we tested 104 cases for
Leptospira IgM antibodies and 45 cases for Leptospira IgG antibodies. We also built
a multivariate logistic model using the purposeful model selection method to evaluate
potential risk factors for the disease. The model was tested for goodness of fit and
validated. We found that hantavirus had an overall prevalence of 12.1% and
Leptospira had 27% prevalence for IgM antibodies with 1.5% for IgG antibodies.
Hantavirus and Leptospira were not statistically found to be probable causes for the
epidemic. The results from the multivariate model found that the use of some types of
protective equipment and access to safe drinking water help to reduce the odds of
disease. Having an immediate family member also increases the odds. While the
results of this study allow us to eliminate hantavirus and Leptospira, it does not
eliminate a possible zoonotic pathogen. Implementing the use of protective
equipment and providing access to safe drinking water may be possible prevention
strategies. Continued investigation is needed to determine the etiology of the
epidemic.
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BACKGROUND
Literature Review
Throughout Central America, an unexplained kidney disease epidemic has been
occurring since the 1990s.1 The cause(s) of this kidney disease remains unknown. The disease is
being called Mesoamerican nephropathy (MeN).1 MeN is characterized by a rapid progression of
kidney disease that is identified when patients present for medical care with chronic kidney
disease of unknown etiology (CKDu).1,2,3 Curiously, the commonly known renal disease risk
factors, such as diabetes and hypertension, are not present in the individuals with MeN.1,4, 5
Previous studies have shown that MeN can also present in cases with acute kidney injury
(AKI).1,6-10 However, most studies investigating MeN focus on patients in the late stages of
disease (CKDu) rather than in the earliest, acute phase (AKI).
One of the countries highly impacted by this epidemic is Nicaragua.1,11,12 Within
Nicaragua, MeN is disproportionately impacting sugarcane workers in Chichigalpa,
Chinandega.1,13,14 One leading hypothesis suggests an infectious agent causing the epidemic.1
Researchers noted the warm, tropical weather patterns for this area alongside occupational and
environmental exposures that could be conducive to infectious disease transmission. 1 A large
rodent population was discovered, which could harbor pathogens potentially responsible for
causing kidney disease that the workers are exposed to in the sugarcane fields. 1 Two possible
infectious rodent-borne pathogens are hantavirus and Leptospira.1 However, the hypothesis of
one of these, or any other agents, as the cause of MeN has not yet been fully examined.
Hantavirus
Hantavirus is a relatively recently described pathogen infecting humans. Hemorrhagic
fever with renal syndrome (HFRS) is one of the major clinical scenarios that results from
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hantavirus infection in humans.13-15 HFRS manifests typically through 4 clinical phases.14,16 In
the first phase, the majority of HFRS cases experience high fevers, flulike symptoms, abdominal
pain, and headaches accompanying the renal syndrome.14 Renal syndrome is characterized by
elevated creatine levels and reduced renal filtration. The real danger of HFRS is the damage to
the vascular system that occurs throughout the body, which can lead to internal hemorrhaging
throughout the capillaries.14 When symptoms are present, antibody detection with seroconversion
and virus isolation are the best diagnostic methods.15 IgM assays can detect antibodies to
hantavirus in serum during the acute infection phase. Using IgM and IgG assays on paired (acute
and convalescent) sera samples can be used to demonstrate seroconversion.15
Throughout the world, rodent population dynamics are strongly connected to hantavirus
epidemics.17,18 In geographical areas highly populated with rats, there are higher numbers of
HFRS cases.19 Rats and mice are the predominant reservoirs and carriers of hantavirus that can
transmit the infection to humans.17 The most common mode of transmission is when infected rat
urine or feces becomes airborne and inhaled by a human.17 For this route of transmission, these
factors must occur: a highly dense carrier population, the carrier’s habitat must be available to
the human, and the human needs to come in contact with the virus while it is viable outside of
the carrier.17 Thus, breaking the link between the carrier and the human could be beneficial to
preventing hantavirus infection. Understanding specific exposures putting people at risk in
settings where hantavirus is known to circulate can ultimately lead to targeted prevention
measures.
In recent years, the frequency of hantavirus infections is rising.17 One study conducted by
Montoya-Ruiz, et al examined the prevalence of hantavirus in 10 nations located in Central and
South America.20 Within the Americas, the monitoring of hantavirus is a more recent

2

development since the 1990s.20 Reports state that there are over 30 different strains of hantavirus
within Central and South America. 20 In their research, they found an outbreak of hantavirus
infection in humans in Panama that was most likely transmitted from rodents.20 Overall, they
found that there is need for improved surveillance of hantavirus in Latin America.
Leptospirosis
Spirochetes of the genus Leptospira cause leptospirosis.19-22 Of all zoonotic infections,
leptospirosis is the most common in the world. 21-22 Globally, there are more than 1 million
people infected by leptospirosis every year.22 This creates a significant global burden of disease.
Nations with tropical and subtropical climates have the highest transmission rates of
leptospirosis.19,21-22 As global warming continues to raise temperatures and alter weather patterns
worldwide, the risk of Leptospira infections will greatly increase.22 In addition, tropical and
subtropical climates are susceptible to leptospirosis epidemics following strong storm systems
with large amounts of rain and flooding.22
Like Hantavirus, rodents are the main carriers of Leptospira, but other mammals can also
carry and transmit Leptospira.22 Also similar to hantavirus, transmission of Leptospira to humans
involves exposure to infected urine.21-22 This can occur through exposure to water and soil that
have been contaminated with infected urine. Within endemic areas, people living in
impoverished areas and people with occupational exposures are the most vulnerable groups for
contracting leptospirosis.22 The occupation with the highest prevalence of leptospirosis is
sugarcane workers.22 A study conducted in Chinandega, Nicaragua, found that almost three-fifths
of sugarcane workers have leptospirosis.22-23 Some possibility of Leptospirosa infection
transmission to sugarcane workers are exposure to infected rats living in the fields, aerosolization
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of infected field soil, and contact with run-off from fields that collect in irrigation and drainage
ditches.22-23
Leptospirosis manifests itself in humans in different ways. There is typically a range of
people experiencing mild to severe symptoms, with only a few individuals will be asymptotic.22
For minor illness, people typically experience a fever, headache, and myalgia, but there can be
more negative consequences from infection.24 For instance, leptospirosis can negatively impact
people through the kidneys by causing renal insufficiency or acute renal failure.24 This can lead
to AKI and CKD in individuals without other risk factors for kidney disease.22 As with
hantavirus, a common practice is to test for IgM and IgG antibodies to Leptospira in humans
presenting with symptoms of leptospirosis.
Numerous studies have examined leptospirosis cases in endemic nations. One example is
a cohort study conducted in Taiwan following a flood which monitored communities to assess a
possible relationship between CKD and leptospirosis.21 Data from that study suggest that CKD
may result from Leptospira infection. A retrospective cohort study conducted by Daher et al in
Brazil looked at clinical data from patients with confirmed leptospirosis.25 Of these cases, nearly
90% presented with AKI.25 Many patients had the common symptoms of leptospirosis such as
fever, headache, myalgia, etc. 25 Most of those patients were young adults.25 Within that
population, they also found that individuals working as farmers had a greater risk of
leptospirosis.25
Public Health Significance
The Pan American Health Organization estimates that over 50,000 individuals have died
prematurely as a result of MeN.1,6, 26 Despite the vast number of lives this epidemic has claimed,
the cause of MeN remains unknown. One of the primary goals of epidemiology is to determine
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the cause(s) of disease in order to stop epidemics and to prevent more individuals from becoming
diseased. Since most individuals with MeN do not have the expected risk factors to develop
kidney disease, something else, possibly an infectious pathogen or pathogens, is causing MeN.1
For this reason, improved surveillance and testing of leptospirosis and hantavirus may be
beneficial in endemic nations experiencing CKDu epidemics. As previously mentioned, prior
studies investigating MeN focused primarily on CKDu cases. The studies that have researched
AKI have done so to document that AKI is a part of the early progression of MeN.6-10 Inasmuch,
there is a need to investigate whether the AKI in the early disease process is linked to
leptospirosis or hantavirus infection and to understand the potential occupational exposures and
behavioral exposures associated with AKI in MeN.
Specific Aims
In Chichigalpa, Chinandega, Nicaragua, there are over 500 sugarcane workers with MeN
working at ISA.1 As throughout Latin American, the cause of the MeN remains a mystery.1 In
Chichigalpa, the sugarcane fields have a high-density population of rodents, and sugarcane
workers spend extended periods of time within these fields, exposing them to infectious diseases
transmitted by rodents. The epidemiology of rodent-borne diseases, such as leptospirosis and
hantavirus, has not been described within this specific population of sugarcane workers and has
not yet been evaluated as the cause of MeN.1
The long-term goal of this study is to discover the cause(s) of MeN and to prevent new
cases from occurring. The overall objective of this proposed thesis is to investigate hantavirus
and leptospirosis as potential causes of MeN. The central hypothesis of this study is that
hantavirus and/or leptospirosis will be more prevalent in individuals with MeN than healthy
individuals. The central hypothesis will be objectively tested through 2 specific aims:
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Aim 1: To determine the prevalence of hantavirus and leptospirosis among cases and
controls through laboratory testing.
Aim 2: To describe and evaluate the differences potential risk factors for MeN through
statistically analyzing interview data from cases of MeN and controls
The expected outcomes of this study are as follows: the cases will have a higher
prevalence of antibodies to Leptospira than controls and higher prevalence of antibodies to
hantavirus than controls. Differences in possible risk factors for MeN between cases and controls
are also expected, with the cases having risk factors for rodent-borne pathogen transmission than
the controls have. The alternative, null hypothesis is that the prevalence of antibodies to
hantavirus and leptospirosis will not be different between cases and controls. Additionally, the
alternative, null hypothesis predicts that there will not be differences in exposures between cases
and controls.
METHODS
Study Design
This is a cross-sectional study to determine if hantavirus infection and/or leptospirosis
may be involved with the MeN epidemic in Nicaragua. This study is being conducted as part of a
larger investigation into the MeN epidemic entitled “Investigation into the Etiology of
Unexplained Kidney Disease in Nicaragua” by researchers at Baylor College of Medicine in
Houston, Texas, and Texas A&M University Health Science Center in College Station, Texas.
Study Setting
The study setting is a commercial sugarcane plantation, Ingenio San Antonio (ISA), in
Chichigalpa, Chinandega, Nicaragua. The area surrounding ISA has been identified as one of the
MeN “hotspots” in Central America as well as a possible epicenter of the MeN epidemic.27 Due
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to this high burden of MeN, this study site is ideal for the etiologic investigation. In February
2015, researchers initiated active surveillance for early-stage MeN disease at ISA’s large, private
hospital, which is located on the plantation grounds. The ISA workers and their families use this
hospital for their primary healthcare needs. Surveillance is currently ongoing.
Study Subjects
To be included in the study, an individual must work at ISA. Over 70% of the subjects
live in Chichigalpa, as well. Most are under the age of 35. See table 1 for a description of the
study population.
Table 1: Sample Demographics

Controls
(N=160)
Age 30+

Yes
No

Cases
(N=584)

P-value for Pearson
Chi2

86
74

235 Pr = 0.002
349

150
13

527 Pr = 0.489
57

77
38
41

396 Pr = <0.001
83
130

Sex
Male
Female
Smoking Status

Number of years
worked at ISA

No, Never
Yes, Former
Yes, Current
<2
3 to 6 years
7 to 10 years
>10

24
54
32
53

136
171
118
112

Pr=0.003

A case is defined as an individual who presented to the emergency department at the
estate’s private hospital and was diagnosed with AKI suspected as due to MeN by the local
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attending physician. For the overarching study, local physicians at the hospital completed case
report forms on each case, and the hospital laboratory reported clinical laboratory findings (urine
analysis, blood chemistry, and hematology). Common complaints were fever, nausea, vomiting,
arthralgia, myalgia, headache, neck and back pain, weakness, and paresthesia. Furthermore, most
cases had evidence of systemic inflammation or immune activation.1 After a case was discharged
from the hospital, a trained study nurse would obtain informed consent into the overarching
study prior to administering an interview about the case’s possible exposures and behaviors at
both work and home. Cases of MeN occur throughout the year. For the purpose of this study,
cases were selected from individuals presenting within the time frame of January 2015 –
February 2017.
A control is defined as an individual who works at the ISA sugarcane plantation and who
has never been diagnosed with MeN or other type of kidney disease. Controls were recruited in
October 2016, during the routine, annual occupational health screenings that are held before each
harvest season. A trained study nurse obtained informed consent and administered an interview
similar to the interview administered to infected cases. The information for cases and controls
has been previously coded with study and sample IDs.
Sample Size Calculation
To calculate the sample size for Aim 1 to determine the prevalence of leptospirosis and
hantavirus infection, the prevalence of Leptospira antibodies in a study sample was first
calculated in a preliminary study, which is 60%.27 The formula used to calculate sample size:
𝑝(1 − 𝑝)(𝑧𝑎/2 )2
𝑛=
𝑑2
For this formula, p is 0.60, 𝑧𝑎/2 is 1.96 for 95% confidence intervals, and d, the absolute error,
was 6.8%. This gave a sample size of 199.39, which was rounded up to 200 for the total sample
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size. The sample size calculation was confirmed through OpenEpi.28 For the ELISA assays, a
sample of 100 controls and 100 cases were drawn for the acute sample testing only. An
additional sample of 75 cases were added to test seroconversion using paired (acute and
convalescent) samples. For aim 2, all individuals on whom interview data was collected will be
used in analysis. The entire universe of data will be analyzed, and no sample will be drawn. For
this reason, a sample size was not calculated. Data include case report forms on 610 case patients
and a subset of interview data on 244 case patients and 163 controls. These data will be included
in the statistical analysis portion.
Data Collection
As part of the larger investigation into the etiology of MeN, the cases and controls are
currently being tested for evidence of exposure to hantavirus and Leptospira via enzyme-linked
immunosorbent assay (ELISA) to detect antibodies (IgM and IgG). For both hantavirus and
Leptospira infections, use of ELISA is common practice to detect antibodies. The ELISA kits for
hantavirus are Focus Diagnotistics IgM, and IgG DxSelectTM (Langenhagen-Hannover,
Germany). The ELISA assay kits for leptospirosis are Virion-Serion (Wurzburg, Germany)
classic Leptospira IgG and IgM tests. The ELISA assays are performed following the
instructions for each kit. The specimens to be tested are selected using simple random sampling
from the sera stored in Houston. The samples are brought to room temperature gradually by
either thawing in the refrigerator overnight or thawing on the lab bench the day of the ELISA
assay. The recommended number of positive controls, negative controls, cut offs, and blanks are
used for each plate run as specified by the kit instructions; all procedures were carried out
according to kit specifications (see Appendix I and II). Serum samples are stored in -80°C
freezers in Houston.
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During the overarching study, any worker presenting with AKI to the ISA hospital were
asked for consent and had a serum sample taken and stored. These individuals were monitored
and followed up with trained cases professionals to see if they would develop MeN.
Convalescent samples were taken after an individual was classified as a case. The sera samples
used for this study are from individuals who did develop MeN. All workers undergo
occupational health screenings prior to employment each harvesting season.1 The serum samples
from controls in this analysis were drawn during the October 2016 screenings, which is when
control workers were enrolled in the study and interviewed about potential exposures of interest,
including demographics, medical history, and possible risk factors (environmental, occupational,
behavioral). For example, some of the information gathered includes drinking water sources,
handwashing practices, exposure to rodents, type of occupation at ISA, etc.
For the cases, the serum collected during hospital admission at the onset of acute kidney
disease were analyzed. In addition, approximately ≥3 months following discharge from the
hospital, convalescent samples were also drawn from cases. For 75 of the cases, paired acute and
convalescent samples were analyzed to evaluate seroconversion from IgM (acute) to IgG
(convalescent) antibodies for hantavirus and Leptospira.
Data Analysis
The statistical analysis portion of the proposed thesis will be broken into two main parts.
Aim 1:
a) Prevalence of Antibodies
The results from the ELISA assays for both hantavirus and leptospirosis will be analyzed
separately, for prevalence ratios between cases and controls. The dependent variable is acute
kidney disease (case status). For each infection, the main independent variable is positive
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serology. A serum sample exhibiting a seropositive test result is defined as ELISA test which is
positive for either IgM or IgG, according to manufacturer protocol, indicating a current, recent,
or past antibody response to pathogen. For a subset of cases, the acute seroconversion rate
between IgM and IgG for hantavirus and Leptospira infections will be calculated for the paired
acute and convalescent samples. Seroconversion is defined as:
1. having IgM negative acute specimen with IgM or IgG positive convalescent specimen
or
2. having IgM positive acute specimen with IgG positive convalescent specimen.

b) Descriptive Statistics
Using data from the case reports and interviews, the prevalence of hantavirus and
leptospirosis will be calculated for each variable individually: sex, age, residence, drug use,
the number of years working at the sugarcane field, type of position at the sugarcane farm,
working in contact with soil, and working in contact with water. Each variable will first be
tested against Pearson’s Chi Test or Fischer’s Exact test if there are too few observations.
Then, for the significant variables, the prevalence ratios with confidence intervals will be
calculated for all of these, using Poisson regression to estimate. In addition, statistical
assessment for potential confounders will be performed. This descriptive analysis will be
conducted separately for Leptospira and hantavirus infection, each using both seropositive
and seroconverted outcomes.
Aim 2: Logistic Regression:
In order to evaluate the impact of hantavirus or Leptospira infection positivity and other
potential exposures in MeN, data from the interviews will also be analyzed alongside the
laboratory testing results to build a logistical model to evaluate each characteristic as a potential
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risk factor, comparing patients with MeN to control workers. The odds ratios with confidence
intervals for the variables selected in the multivariate model will be reported. See Table 2 for a
list of variables to be tested for the model. The response variable is MeN case status. A subset of
the dataset with complete interview information will be used for model building. The purposeful
model selection steps as defined by Hosmer, Lemeshow, and Sturdivant will be used for model
selection.29
Table 2: Variables to be included in model selection
Sex
Number of years
working at ISA
Have seen rodents in
the fields at work

Age
Type of position at
ISA
Have seen rodents at
home

Protective gear use
Family history of
Mesoamerican
Nephropathy

Own pets

Residence location
Contact with soil
while working
Hand washing
practices at work and
home
Gardening as a hobby

Drug use
Contact with water
while working
Drinking water
sources at work and
home
Medical history

First, a univariable analysis will be conducted individually for each potential variable
using the likelihood ratio (LR) test. Categorical variables with multiple levels will be tested
using the LR test followed by a contingency table analysis to confirm the decision to keep or
drop the variable. All variables that have a p-value less than 0.25 will be used to run one large
multivariate logistical model. The LR test will be used to determine which variables to exclude
and to include using a p-value of 0.05 or less. Each excluded variable will be individually added
to the model and tested again using the LR test to see if it is a significant variable. If it is
significant, a LR test between the model with the added variable compared to the null model will
determine if the variable will be included in the next step of model building. Retained variables
will form the preliminary main effects model. Prior to moving to the next step of the purposeful
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model selection, the variables that were excluded during the univariate analysis will be added to
the model individually and then tested using the LR test. If they are significant, they will be
added to the model.
For all the continuous variables in the model, linearity will be tested using a Lowess
smooth plot. Variables that demonstrate linearity will be included in the model. The variables
that break linearity will be transformed through fractional polynomials and cubic spline functions
to see if the linearity is fixed. The models generated will then be tested against the original
preliminary effects model. If the LR test is significant, the transformed variable will be included
in the model.
Before accepting the final model, any biologically plausible interactions will be tested.
Each biologically plausible interaction term will be tested individually in the model. The LR test
will be kept in the model if the results are significant. The final preliminary model will be
complete, and the AIC will be tested.
Prior to accepting the model, two methods will be used to assess the goodness of fit: The
Pearson χ2 Goodness of Fit test and Hosmer-Lemeshow Test using 10 groups. Comparison of the
AICs, log likelihoods, LR test, R2, Pearson χ2 Goodness of fit, and the Hosmer-Lemeshow test
will be used to assess the model. Finally, the model will be also be validated in STATA. The
dataset will be run through STATA’s stepwise model building program, and the generated model
will be compared to the model built through the purposeful selection.
After the final model is built, the data will then be interpreted through the model. The odd
ratios with confidence intervals of each variable included in the final model will be assessed.
This information will be used to guide future steps in the investigation of MeN.
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Human Subjects
The IRB approval for this study is from the Baylor College of Medicine. The Principal
Investigator Dr. Kristy Murray granted permission to analyze data and specimens. The study was
also reviewed and approved by the ethics boards at the Nicaragua Ministry of Health and by the
Medical Directors of the Hospital Alfredo Chamorro Pellas and Gerencia de Salud Ocupacional
at ISA. Participants who were interviewed gave consent for the use of the interview data and
samples. Data from individuals who were not interviewed were exempted from consent by all
ethics boards. All data from participants used in the study has been deidentified to protect
participants. The thesis proposal was submitted to iRIS of the UTHealth system on August 13,
2018, for approval, and it was approved on September 6, 2018.
RESULTS
Specific Aim 1: ELISA Lab Results for Hantavirus and Leptospira
A total of 199 patients were tested for IgG and IgM antibodies to hantavirus (149 cases
and 50 controls). A total of 90 paired acute and convalescent sera samples from cases were tested
for seroconversion in antibodies to hantavirus. A total of 196 patients were tested for IgM
antibodies to Leptospira (104 cases and 92 controls), and a total of 137 patients were tested for
IgG antibodies to Leptospira (92 controls and 45 cases). The results of the ELISA Hantavirus
IgM and IgG are displayed below in Table 3.
The prevalence of hantavirus IgG antibodies is 9.6% among all tested samples with 6.7%
of cases testing positive and 18% of controls testing positive. The odds of testing negative for
IgG among cases were more than 3 times as likely than among controls. The test of homogeneity
between cases and controls was significant for hantavirus IgG results, but not for hantavirus IgM
results. For IgM hantavirus antibodies, only 3.4% of the cases tested positive with none of the
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controls testing positive. Of the 90 paired acute and convalescent samples, there was 6.67%
(n=6) seroconversion rate.
Table 3: ELISA Results
ELISA Results
Hantavirus IgG
Control
Case
Total

Negative

Positive

Total

41 (82%)
139 (93%)
180 (90%)

9 (18%)
10 (7%)
19 (10%)

50
149
199

Test of Homogeneity Pvalue =0.191

Hantavirus IgM
Control
Case
Total

50 (100%)
144 (97%)
194 (97.5%)

0 (0%)
5 (3%)
5 (2.5%)

50
149
199

Test of Homogeneity Pvalue=0.019

Leptospira IgG
Control
Case
Total

90 (98%)
45 (100%)
135 (98.5%)

2 (2%)
0 (0%)
2 (1.5%)

92
45
137

Test of Homogeneity Pvalue =0.3208

Leptospira IgM
Control
Cases
Total

Negative
63 (68%)
80 (77%)
143 (73%)

Positive
29 (32%)
24 (23%)
53 (27%)

Total
92
104
196

Test of homogeneity pvalue= 0.1852

The possible exposure factors were each tested against the positive hantavirus ELISA
results for IgM and IgG. None of them were significant, except for three variables. The first one
was the difference between cases and controls testing positive for hantavirus IgG antibodies.
More controls than cases tested positive for IgG antibodies (PR 0.373 [CI 0.160-0.867];
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p=0.032). The second is the IgM result for individuals who have contact with rain water while
working. Individuals testing positive for hantavirus were more than 10 times as likely to have
contact with rain water than those who did not (PR 10.6 [1.64-68.8]; p=0.018). The third and last
significant result was for an IgG hantavirus positive antibody result and for those who currently
drink alcohol and/or used to drink alcohol. For the individuals who have ever drank alcohol, they
were significantly less likely to test positive for IgG hantavirus antibodies than those who have
never drank alcohol (PR 0.108 [0.014-0.860]; p=0.035).
Specific Aim 2: MeN Multivariate Model
The results from the univariate analysis are displayed in Table 4. See Appendix VI for the
results of all the variables examined. A total of 107 variables were examined prior to being
analyzed to build a statistical model. The final model is log[casecontrol] = -1.958[work involves
contact with the field] - 1.343[handwash using clean municipal water] + 2.567[drank from a
particular well in the field] – 2.597[drinks from wells in general] – 0.949[ uses protective gloves]
+ 1.38[wears protective long sleeves] + 1.402[has an immediate family member with MeN] –
0.793[has smoked] -1.132[has had moonshine] + 1.474[sees rats in the field while working] –
1.94[works in the field in general] – 1.472 [wears protective eye glasses] + 1.01}. Table 5
displays the results of the final statistical model predicting MeN. The model passed the goodness
of fit testing as well as the validation step.
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Table 4: Univariate Analysis with Whole Dataset
Variable

Cases
(n/N)
527/584
(90%)

OR

Std
Error

Z

747

Control
(n/N)
150/163
(92%)

1.248

0.401

0.690

0.490

0.665

2.341

744

86/160
(23%)

235/584
(40%)

0.579

0.104

3.040

0.002

0.407

0.824

744

119/160
(74%)

389/584
(66.7%)

0.687

0.138

1.860

0.062

0.463

1.020

744

45/160
(28%)

132/584
(23%)

0.746

0.151

1.450

0.147

0.503

1.108

739

100/159
(63%)

377/580
(65%)

1.096

0.204

0.490

0.623

0.761

1.577

12/161
(7.5%)

28/560
(5%)

0.661

0.237

-1.16

0.248

0.328

1.333

28/560
(5%)
15/161
(9%)

17/560
(3%)
45/560
(8%)

1.606

1.017

0.75

0.454

0.464

5.557

0.850

0.266

0.520

0.604

0.461

1.569

24/163
(15%)
86/163
(53%)
53/163
(33%)

136/537
(25%)
289/537
(54%)
112/537
(21%)

0.593

0.150

-2.06

0.039

0.361

0.974

0.373

0.103

-3.56

<0.001

0.217

0.642

5/163
(3%)

18/244
(7%)
2.517

1.299

1.790

0.074

0.915

6.920

27/163
(17%)

15/244
(6%)
0.330

0.112

3.260

0.001

0.170

0.642

Obs

Sex (Males)

P-Value

Confidence
Intervals

AGE CATEGORIES
Above the age of 30

Above the age of 25

Above the age of 35
Resides in Chichigalpa

DRUG USE

721

Yes, former
Yes, current
Have Ever Used Drugs
TOTAL YEARS
WORKED AT ISA

700

<2 years
3-10 years
>10 years
OCCUPATION
Workings in
carrying/hauling
Works as General
Harvester

407

407
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Variable

Obs

Control
(n/N)

Cases
(n/N)

39/163
(24%)
5/163
(3%)
2/163
(1%)
29/163
(18%)

43/244
(18%)
15/244
(6%)
18/244
(7%)
42/244
(17%)

15/163
(9%)
2/163
(1%)
115/163
(71%)
103/163
(63%)
68/163
(42%)
71/163
(44%)
69/163
(42%)

8/244
(3%)
6/244
(2.5%)
89/207
(43%)
10/12
(83%)
5/76
(7%)
4/76
(5%)
7/76
(9%)

116/148
(78%)
60/130
(46%)
19/148
(13%)
66/147
(45%)

43/54
(80%)
18/54
(33%)
15/54
(28%)
18/49
(37%)

120/163
(74%)
27/163
(17%)

161/244
(66%)
8/244
(3%)

OR

Std
Error

P-Value

0.680

0.169

0.121

0.418

1.108

3.389

3.729

0.267

0.392

29.278

6.411

4.824

0.014

1.467

28.019

0.961

0.255

0.880

0.571

1.618

0.334

0.151

0.015

0.138

0.808

2.029

1.670

0.390

0.405

10.181

0.315

0.07

<0.001

0.204

0.486

2.913

2.305

0.177

0.617

13.739

0.098

0.048

< 0.001

0.038

0.257

0.072

0.039

< 0.001

0.025

0.206

0.138

0.059

< 0.001

0.060

0.319

1.078

0.423

0.848

0.500

2.327

0.583

0.197

0.111

0.301

1.132

2.611

1.020

0.014

1.214

5.617

0.713

0.242

0.318

0.366

1.386

0.695

0.155

0.103

0.449

1.077

0.171

0.071

0.000

0.075

0.386

Confidence
Intervals

OCCUPATION
CONTINUED
Works in planting
Pest Control
Weed Control
Works in
Irrigation/Drainage
Auto mechanic
occup_fabrica
Work involves contact
with the field
Works with soil
Works with dry soil
Works with wet soil
Works with soil in the
field
RODENT EXPOSURE
IN HOUSE
Sees rats in house
Sees rat feces in house
Sees rats in house every
day
Sees rats in house
frequently
HANDWASH
PRACTICES
Handwashes hands with
water from house
Handwashes with clean
municipal water

407
407
407

407
407
407
370
175
239
239
239

202
184
202
196

407
407
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Variable
HANDWASH
PRACTICES
Handwash with from
municipal truck water
Handwashes with ditch
water
Handwashes with water
from drainage tube
Handwashes with well
water
Always washes hands
before eating
Usually washes hands
before eating
Rarely washes hands
before eating
Never washes hands
before eating
DRINKING WATER
SOURCE
Drink from clean
municipal water
Drink from potable water
truck
Drink from a particular
well in ISA’s field
Drink from water in a
ditch
Drink from drainage pipe
Drink from drainage tube

Obs

407
407
407
407
407
407
407
407

407
407
407
407
407
407

Control
(n/N)

Cases
(n/N)

7/163
(4%)
4/163
(2.5%)
1/163
(0.6%)
5/163
(3%)
138/163
(85%)
17/163
(10%)
4/163
(2.5%)
4/163
(2.5%)

19/244
(8%)
12/244
(5%)
16/244
(7%)
13/244
(5%)
182/244
(75%)
30/244
(12%)
12/244
(5%)
12/244
(5%)

35/163
(21%)
9/163
(6%)
7/163
(4%)
1/163
(0.6%)
1/163
(0.6%)
2/163
(1%)

11/244
(5%)
11/244
(5%)
22/244
(9%)
6/244
(2%)
9/244
(4%)
15/244
(6%)

126/142
(89%)
98/124
(79%)
64/140
(46%)
40/140
(29%)
113/141
(80%)

157/234
(67%)
84/236
(36%)
49/233
(21%)
35/232
(15%)
228/238
(96%)

Confidence
Intervals

OR

P-Value

1.882

0.164

0.773

4.584

2.056

0.219

0.651

6.490

11.368

0.019

1.493

86.586

1.778

0.283

0.622

5.087

0.532

0.016

0.318

0.889

1.204

0.564

0.641

2.263

2.056

0.219

0.651

6.490

2.056

0.219

0.651

6.490

0.173

0.000

0.085

0.352

0.808

0.644

0.327

1.995

2.208

0.076

0.921

5.297

4.084

0.195

0.487

34.243

6.204

0.085

0.778

49.446

5.273

0.029

1.189

23.376

0.259

< 0.001

0.144

0.466

0.248

< 0.001

0.159

0.387

0.316

< 0.001

0.200

0.500

0.444

0.002

0.266

0.742

5.650

< 0.001

2.652

12.037

USE OF PROTECTIVE
EQUIPMENT
Wears gloves
Wears protective eye
glasses
Wears mask over mouth
Wears mask over mouth
and nose
Wears long sleeves

376
378
373
372
379
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Variable
Wears boots
FAMILY HISTORY OF
MeN
Family member with
MeN
Immediate family
member with MeN
(parent or sibling)

Obs
380

371

Control
(n/N)
139/141
(99%)

Cases
(n/N)
236/239
(99%)

48/141
(34%)
32/141
(23%)

140/230
(61%)
119/141
(84%)

371
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OR

P-Value

Confidence
Intervals

1.132

0.893

0.187

3.014

< 0.001

1.946

4.668

3.652

< 0.001

2.279

5.851

6.857

Table 5: Prediction Model for MeN
Case Control
OCCUPATION BASED
Work involves contact
with field
Sees rats in the field
while working
Works as a general
harvester
WATER SOURCES
Handwashing with clean
municipal water sources
Drinking from a
particular well in the
field
Drinking water from
well water in general

Odds Ratio

Std. Err.

P>z

[95%
Conf.

Interval]

0.141

0.053

<.001

0.067

0.296

4.368

2.038

0.002

1.751

10.899

0.303

0.168

0.032

0.102

0.900

0.261

0.157

0.026

0.080

0.850

13.027

9.829

0.001

2.969

57.158

0.074

0.037

<0.001

0.028

0.199

0.387

0.164

0.025

0.169

0.889

0.229

0.092

<0.001

0.105

0.503

3.961

2.103

0.010

1.399

11.211

4.063

1.472

<0.001

1.998

8.264

0.452

0.157

0.023

0.229

0.895

0.323

0.165

0.027

0.119

0.878

2.745

2.124

0.192

0.602

12.508

USE OF PROTECTIVE
EQUIPMENT/GEAR
Wear gloves
Wear protective eye
glasses
Wear long sleeves
Family history of CKD
(sibling or parent)
History of smoking
History of drinking
moonshine
_cons
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DISCUSSION
The results from the ELISAs do not support the hypothesis that hantavirus is causing
MeN. The prevalence of testing positive to hantavirus IgG antibodies signaling a possible
previous infection is low with an 18% prevalence among controls and 6.7% among cases. The
significant result of the homogeneity test suggests that cases may be less likely to have had a
hantavirus infection in the past than the controls. The POR of testing positive for IgG antibodies
to hantavirus for cases was 0.373 against controls which also supports that cases are less likely to
have had hantavirus in the past. However, only 3.4% of cases have IgM antibodies to the
hantavirus with none of the controls testing positive for IgM antibodies to the hantavirus. While
there was a significant POR for those who work with rain water and testing positive for
hantavirus IgM antibodies, the confidence interval was very broad. Overall, the IgM and IgG
ELISA results do not support further investigation into hantavirus as a potential causative agent
for MeN in Nicaragua.
The univariate analysis results suggest numerous risk factors for MeN as well as some of
confounding factors. For instance, age is found to be highly significant within the dataset.
Individuals younger than 30 appear to have nearly 50% greater odds of suffering MeN than those
30 or older than 30. However, most of the workers are 30 years of age or younger, which
potentially skews the result. Another example of this is the total number of years worked at ISA,
which suggests the more years worked at ISA as being protective against MeN. However, the
majority of the workers are young, seasonal workers with less totaled years accrued at ISA, and
this could skew the results as well.
The data also suggest that the type of position that the study population work at ISA
impact their risk of MeN. For the individuals working with weed control, their risk of MeN is
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greater than 6 times greater than other positions. Another protective factor against MeN was for
individuals that worked as automotive mechanics as opposed to workers who worked in other
locations. Working as an automotive mechanic most likely has very different occupational
exposures as compared to those working in the fields, and it is very possible that they are not
exposed to the risk factor(s) that increase the likelihood of a person developing MeN. In our
analysis, the individuals with positions for the harvest or dealing with soil had significantly less
risk for developing MeN. However, this relationship is unclear, since MeN has long been
identified as a disease of agricultural field workers. While the variables dealing specifically for
working with soil had too few observations to be examined later in the model building portion,
there were enough data points to include a joint variable for working with soil or water in the
model building step.
Another significant risk factor was exposure to rodents at home or during work. There
were not enough data on individuals seeing rats at home to be examined in the model building
step. However, the univariate analysis found that those seeing rats within the home daily had
significantly higher odds of developing MeN than those who did not. Furthermore, individuals
who saw rats in the field were 3.615 times more likely to have MeN than those who did not.
There was enough data on seeing rats in the field to be included in the model building process,
and it was included in the final model as displayed in Table #. The significance of being exposed
to rats does support the hypothesis that a rodent-borne agent could be a causative agent of the
MeN epidemic. since workers who reported encountering rodents i8n the field were more likely
to be MeN case patients.
Water exposures were also found to be significantly associated with disease. For instance,
handwashing using fountain water was highly protective, and handwashing with drainage tube
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water drastically increased the odds of the MeN. Similarly, drinking water from the fountain
significantly protected against MeN, and drinking water from the drainage pipe in the field
severely increased the odds of MeN. The type of water exposures for individuals also played a
significant role in the final predicting model as well. Unclean water is a known risk factor for
many diseases due to containing infectious pathogens, including Leptospira, and harmful
chemicals. The unsafe water exposures support an environment exposure contributing to and/or
causing the MeN epidemic. When examining our findings about a potential role of drinking
water source in conjunction with the added risk for MeN associated with exposure to rats, these
data support to the hypothesis of Leptospira or a different zoonotic disease being a possible
causative agent of MeN.
In both the univariate analysis and predictive model, the use of protective personal
equipment was mostly found to be protective against MeN. In particular, the use of gloves,
protective eye glasses, face mask, and nose protective equipment all significantly reduce the
odds of MeN. It is possible that these types of personal protective equipment may help to reduce
or prevent exposure(s) that lead to the development of MeN, such as by interrupting the
transmission route of a pathogen or other agent. Interestingly, wearing long sleeves was found to
increase the odds of MeN in both the univariate analysis and the final model. This does warrant
further investigation as it could potentially suggest that heat exhaustion may be a contributing
factor or possibly exacerbate the condition of MeN.
Lastly, having a family member with MeN was found to increase the odds of an
individual having MeN in both the univariate analysis and the predictive model. It is important to
note that the cases do not have any of the risk factors to develop kidney at a young age, but it is
possible that there is a genetic component that make individuals more susceptible to developing
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MeN. It is also possible that the family members work together or within the same area at ISA,
which would mean that they potentially have the same occupational exposures.
The predictive logistic model results mostly agreed with the univariate results, but there
were a few differences in the predictive model. Curiously, drinking well water in the field was
found to significantly increase the odds of MeN, but drinking well water at home or work was
found to be protective. This does merit further investigation as it could suggest that there is a
specific exposure that the well in the field contains that the other wells do not contain. The
confidence interval was bit broad for the variable which a larger data sample may be able to
address. Within the model, the factors of being a fieldworker, using fountain water to wash one’s
hands, drinking well water at home and work (but not in the field), history of smoking, and
drinking local moonshine/lija were all found to reduce the odds of MeN. The factors of seeing
rats in the field, drinking from a well in the field, wearing long sleeves, and having a family
member with MeN increased the odds of MeN among cases and controls.
When examining the logistic predictive model in Table 5, the model fits well given the
constraints from the dataset. Most of the confidence intervals were narrow, except for the
variables representing the well in the field, wearing sleeves, having a family member with MeN,
and seeing rats in the field. These all had increased odds ratios with significant p-values, but the
confidence intervals were not narrow. Due to working with a smaller dataset, these variables do
necessitate further investigation with more data.
Despite the valuable information gleaned from this analysis, there are a few weaknesses.
Since we analyzed data and biologic specimens that had already been collected, we were only
able to analyze what was available. Not all individuals with MeN completed interviews, and
some workers in this study declined to answer some questions during the interview, which means
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we did not have complete information for all individuals for all variables of interest. For the
multivariate analysis, in particular, we were limited to analyzing a subset of individuals with
more complete dataset. The data subset had a total of 407 observations with some missing values
for variables. Most of the variables were able to be included in the model building process, but
there were a few variables that were excluded due to having too many missing observations.
However, the univariate analysis and the statistical model still provide valuable information for
future studies. In addition, statistical power was met with the sample sizes for the ELISAs, and
the results help to guide future studies to investigate other possible infectious agents. A
prospective case control study in the future would be highly beneficial to further investigate the
MeN epidemic in Nicaragua, as well as define specific opportunities to interrupt transmission of
hantavirus and Leptospira.
CONCLUSION
We found a very low level of exposure to hantavirus in this agriculture worker population
in Nicaragua. We also found a low prevalence of Leptospira among cases and controls. While
these results do not support hantavirus or Leptospira as sources of the MeN epidemic, the data
do not eliminate a different infectious pathogen as a possible source of MeN. The association
between seeing rats in the field and MeN do suggest a possible zoonotic disease causing MeN,
and the results of this study support eliminating Leptospira. From the ELISA results, it may be
useful for the local health departments to have routine testing and treatment available for
Leptospira. Other useful applications of the results of this study would be explore any factors
that put the agricultural workers at risk for exposure to hantavirus. Since we found controls in
this study had more often been exposed to hantavirus, there may be specific high risk groups for
that disease that could warrant investigation for future preventive measures.
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We evaluated potential risk factors for MeN. We found an the association between
several important environmental exposures and MeN, since individuals with MeN working at
ISA had more frequent exposures to potential environmental and occupational risk factors than
their healthy worker counterparts. We also discovered that several factors seemed to protect
against MeN and could lead to possible intervention strategies. Namely, the provision of safe
drinking water and use of PPE could reduce the occurence MeN in this population. Given that
risk factors for MeN identified herein overlap with known risk factors for infectious disease,
particularly hantavirus and Leptospira, our data do support the hypothesis of an infectious agent
or an environmental agent as possible contributing factors to MeN within this study population.
Our findings contribute to a deeper understanding of the environmental exposures for the
sugarcane workers, and continued investigations into possible infectious agents contributing to
the MeN epidemic are needed.
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APPENDICES
Appendix I: Hantavirus ELISA Kit Instructions
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Appendix II: Leptospira ELISA Kit Instructions

SERION ELISA classic Leptospira IgG/IgM
CONTENTS

1. INTENDED USE: For sale in the U.S. for Research Use Only. Not for use in diagnostic
procedures.
2. BACKGROUND
3. SERION ELISA classic - TEST PRINCIPLE
4. COMPONENTS OF THE KIT
5. MATERIAL REQUIRED BUT NOT SUPPLIED
6. STORAGE AND STABILITY
7. TEST PROCEDURE SERION ELISA classic
7.1 Evidence of deterioration
7.2 Sample preparation and storage
7.3 Preparation of kit reagents
7.4 Overview - test procedure
7.5 Test procedure
8. TEST EVALUATION
8.1 Single-point quantification with the 4PL method
8.2 Criteria of validity
8.3 Calculation SERION ELISA classic Leptospira IgG/IgM (quantitative)
9. STATEMENTS OF WARNING
9.1 Statements of warning
9.2 Disposal
10. BIBLIOGRAPHY
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SERION ELISA classic Leptospira IgG/IgM
ENZYME IMMUNOASSAY FOR DETECTION OF HUMAN ANTIBODIES (IGG/IGM)

For sale in the U.S. for Research Use Only. Not for use in diagnodtic procedures.
IgG-Kit (quantitative)
IgM-Kit (quantitative)

order number:
order number:

ESR125G
ESR125M

Tests evaluated: Dade Behring BEP ® III / BEP ® 2000, DSX, manually

1. INTENDED USE

SERION ELISA CLASSIC LEPTOSPIRA IGG/IGM ARE QUANTITATIVE UND
QUALITATIVE TESTS FOR DETECTION OF GENUS-SPECIFIC HUMAN
ANTIBODIES AGAINST LEPTOSPIRA IN SERUM OR PLASMA. FOR SALE IN THE
U.S. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
2. BACKGROUND

LEPTOSPIRES ARE SPIRAL-SHAPED, GRAM-NEGATIVE, OBLIGATE AEROBIC
SPIROCHETES WITH INTERNAL FLAGELLA. THE GENUS IS DIVIDED INTO TWO
SPECIES, THE PATHOGENIC LEPTOSPIRA INTERROGANS AND THE FREELIVING NONPATHOGENIC LEPTOSPIRA BIFLEXA. LEPTOSPIRA INTERROGANS
HAS ABOUT 200 DIFFERENT SEROVARS BASED ON THE VARIABILITY OF
SURFACE ANTIGENS. LEPTOSPIRES AFFECT MAMMALS (WILD AND
DOMESTIC ANIMALS), REPTILES AND AMPHIBIANS; THEY MAY BE SHED IN
THE URINE LIFELONG. RATS AND OTHER RODENTS ARE PRIMARY
RESERVOIRS FOR HUMAN INFECTION. INFECTION IS TRANSMITTED BY
URINE-CONTAMINATED SOIL OR WATER, RAT BITES OR ANIMAL TISSUE.
ESPECIALLY OCCUPATIONAL GROUPS LIKE AGRICULTURISTS, PLUMBERS,
MINE WORKERS, FISHERMEN AND MEAT- INDUSTRY WORKERS ARE AT
GREAT RISK OF EXPOSURE.
MUCOSA AND SKIN LESIONS ARE THE MOST LIKELY SITES OF ENTRY FOR
LEPTOSPIRES (FIG. 1). BACTERIA MAINLY PROLIFERATE IN THE CENTRAL
NERVOUS SYSTEM, KIDNEYS AND LIVER.
Figure 1.
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THE IMMUNE SYSTEM REMOVES ORGANISMS FROM BLOOD AND ORGANS
WITHIN 4-7 DAYS BY COMPLEMENT AND HUMORAL IMMUNITY. CELLMEDIATED IMMUNITY DOES NOT APPEAR TO BE IMPORTANT. LEPTOSPIRES
WITHIN THE CONVOLUTED TUBULES OF THE KIDNEYS MAY SURVIVE DUE
TO THE INEFFICIENCY OF THE IMMUNE SYSTEM, THE COMPLEMENT SYSTEM
IN PARTICULAR. FOR THIS REASON INFECTIOUS LEPTOSPIRES ARE SHED IN
URINE.
MICRO-AGGLUTINATION TESTS, ELISAS AND INDIRECT FLUORESCENCEANTIBODY TESTS ARE MOST FREQUENTLY USED FOR SERODIAGNOSIS.
3. SERION ELISA classic - TEST PRINCIPLE
Microtest plates are coated with antigens. This constitutes the solid phase. Sample is added to the
plates and any antibodies specific for the antigen present will bind to the solid phase. After removal of
unbound material, anti-human IgG, IgA or IgM conjugated to an enzyme (alkaline phosphatase) is
allowed to react with the immune complex. After removal of excess conjugate by washing, an
appropriate substrate (para-nitrophenylphosphate) is added, with which the conjugated enzyme
reacts producing a colored derivative of the substrate. The color intensity is proportional to the level
of specific antibody bound and can be quantified photometrically.
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4. COMPONENTS OF THE KIT
Test components

amount /
volume

Break apart microtiter test strips each with 8 antigen coated single wells (altogether 96),
1 frame
the coating material is inactivated

12

Standard serum (ready-to-use)
Human serum in phosphate buffer with protein; negative for anti-HIV-Ab, anti-HBs-Ag
(Hepatitis B-Virus-surface antigen) and anti-HCV-Ab; preservative: < 0.1 % sodium azide
coloring: Amaranth O

2 x 2 ml

Negative control serum (ready-to-use)
Human serum in phosphate buffer with protein; negative for anti-HIV, anti-HBs (Hepatitis BVirus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide
coloring: Lissamin green V

2 ml

Anti-human-IgG-, IgA-, IgM-conjugate (ready-to-use)
Anti-human-IgG, -IgA, -IgM from goat (polyclonal), conjugated to alkaline phosphatase,
stabilized with protein stabilization solution
preservative: 0.01 % methylisothiazolone, 0.01 % bromnitrodioxane

13 ml

Washing solution concentrate (sufficient for 1 litre)
Sodium chloride solution with Tween 20, 30 mM Tris
preservative: < 0.1 % sodium azide

33.3 ml

Dilution buffer
Phosphate buffer with protein and Tween 20;
preservative: < 0.1 % sodium azide
0.01 g/l Bromphenol blue sodium salt

2 x 50 ml

Stopping solution
1.2 N sodium hydroxide

15 ml

Substrate (ready-to-use)
Para-nitrophenylphosphate, solvent free buffer
preservative: < 0.1 % sodium azide
(Substrate in unopened bottle may have a slightly yellow color. This does not reduce the
quality of the product!)

13 ml

Quality control certificate with standard curve and evaluation table
(quantification of antibodies in IU/ml or U/ml)
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5. MATERIAL REQUIRED BUT NOT SUPPLIED
-

common laboratory equipment

-

for the IgM-ELISA: SERION Rf-Absorbent (Order no. Z200/20ml)

-

photometer for microtiter plates with filter, wavelength 405 nm, recommended
reference wavelength 620 nm - 690 nm (e.g. 650 nm)

-

incubator 37°C

-

moist chamber

-

distilled water

6. STORAGE AND STABILITY
Reagent

Storage

Stability

microtiter strips
(antigen)

after opening at 2-8°C in closed aluminum bag with
desiccant

4 weeks

Strips which are not used must be stored in the press-seal bag
of aluminum compound foil under dry and airtight
conditions!
control sera /
standard sera

after opening at 2-8°C

conjugate

ready-to-use solution, at 2-8°C
Avoid contamination (sterile tips!)

dilution buffer

after opening at 2-8°C
Discard cloudy solutions!

24 months

unopened
washing solution

until expiry date;
24 months from
date of production
until expiry date
28 months from
date of production

concentrate after opening at 2-8°C
working dilution at 2-8°C
working dilution at room temperature

until expiry date;
36 months from
date of production
until expiry date
2 weeks
1 week

Bottles used for the working dilution should be cleaned
regularly, discard cloudy solutions.
substrate

ready-to-use solution at 2-8°C, protected from light!
Avoid contamination (sterile tips!) Discard when solution
turns yellow (extinction against distilled water > 0.25).

stopping solution

after opening at room temperature
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until expiry date
24 months from
date of production

until expiry date

7. TEST PROCEDURE SERION ELISA classic
7.1 Evidence of deterioration

ONLY USE SERION ELISA CLASSIC REAGENTS FOR TEST PROCEDURE, SINCE
ALL REAGENTS ARE MATCHED. IN PARTICULAR STANDARD AND CONTROL
SERA ARE DEFINED EXCLUSIVELY FOR THE TEST KIT TO BE USED. DO NOT
USE THEM IN OTHER LOTS. DILUTION BUFFER, WASHING SOLUTION AND
SUBSTRATE SOLUTION CAN BE USED FOR ALL SERION ELISA CLASSIC KITS
IRRESPECTIVE OF THE LOT AND THE TEST.
THERE ARE THREE DIFFERENT CONJUGATE CONCENTRATIONS FOR EACH
IMMUNOGLOBULIN CLASS: LOW, MEDIUM, HIGH
THE CLASSIFICATION IS WRITTEN ON EACH LABEL AS FOLLOWS:
E.G.

IGG + LOWLY CONCENTRATED IGG
CONJUGATE IGG ++ MEDIUM
CONCENTRATED IGG CONJUGATE
IGG +++ HIGHLY CONCENTRATED
IGG CONJUGATE

IN RARE CASES THE USE OF SPECIAL CONJUGATE IS NECESSARY TO
GUARANTEE CONSISTENT QUALITY FOR OUR PRODUCTS. SPECIAL
CONJUGATES ARE PRODUCED IN A SEPARATE LOT AND DO NOT WEAR THE
“+” SIGN. THEREFORE, SPECIAL CONJUGATES ARE NOT EXCHANGEABLE
WITH OTHER CONJUGATES.
Please pay close attention to notifications on labels!

UNOPENED, ALL COMPONENTS OF THE SERION ELISA CLASSIC KITS MAY BE
USED UP TO THE DATES GIVEN ON THE LABELS, IF STORED AT +2°C TO +8°C.
COMPLETE STABILITY AND STORAGE DATA ARE DESCRIBED UNDER “6.
STORAGE AND STABILITY”.
EACH REAGENT HAS BEEN CALIBRATED AND OPTIMIZED FOR THE TEST.
DILUTION OR ALTERATION OF THESE REAGENTS MAY RESULT IN A LOSS OF
SENSITIVITY.
AVOID EXPOSURE OF REAGENTS TO STRONG LIGHT DURING STORAGE AND
INCUBATION. REAGENTS MUST BE TIGHTLY CLOSED TO AVOID
EVAPORATION AND CONTAMINATION WITH MICROORGANISMS SINCE
INCORRECT TEST RESULTS COULD OCCUR DUE TO INTERFERENCE FROM
PROTEOLYTIC ENZYMES.
TO OPEN THE PRESS-SEAL BAG PLEASE CUT OFF THE TOP OF THE MARKED
SIDE, ONLY. DO NOT USE THE STRIPS IF THE ALUMINUM BAG IS DAMAGED
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OR IF THE PRESS-SEAL BAG WITH REMAINING STRIPS AND DESICCANT WAS
NOT PROPERLY CLOSED.
BRING ALL REAGENTS TO ROOM TEMPERATURE BEFORE TESTING.
USE ASEPTIC TECHNIQUES FOR REMOVING ALIQUOTS FROM THE REAGENT
TUBES TO AVOID CONTAMINATION. TO AVOID FALSE POSITIVE RESULTS
ENSURE NOT TO CONTACT OR SPRINKLE THE TOP-WALLS OF WELLS WHILE
PIPETTING CONJUGATE. BE CAREFUL NOT TO MIX THE CAPS OF THE BOTTLES
AND/OR VIALS. REPRODUCIBILITY DEPENDS ON THOROUGH MIXING OF THE
REAGENTS. SHAKE THE FLASKS CONTAINING CONTROL SERA BEFORE USE
AND ALSO ALL SAMPLES AFTER DILUTION (E.G. BY USING A MONOMIXER).
BE SURE TO PIPETTE CAREFULLY AND COMPLY WITH THE GIVEN
INCUBATION TIMES AND TEMPERATURES. SIGNIFICANT TIME DIFFERENCES
BETWEEN PIPETTING THE FIRST AND LAST WELL OF THE MICROTITER PLATE
WHEN FILLING SAMPLES/CONTROL SERA, CONJUGATE OR SUBSTRATE MAY
RESULT IN DIFFERENT
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„PRE INCUBATION“ TIMES, WHICH MAY INFLUENCE THE PRECISION AND
REPRODUCIBILITY OF THE RESULTS.
OPTIMUM RESULTS CAN ONLY BE ACHIEVED IF SERION ELISA CLASSIC
INSTRUCTIONS ARE FOLLOWED STRICTLY.
THE TEST IS NOT VALID, IF THE LOT-SPECIFIC VALIDATION CRITERIA ON THE
QUALITY CONTROL CERTIFICATE ARE NOT FULFILLED.
INADEQUATE WASHING WILL AFFECT THE TEST RESULTS:
THE WASHING PROCEDURE SHOULD BE CARRIED OUT CAREFULLY. IF THE
WASHING PROCEDURE IS CARRIED OUT AUTOMATICALLY FOLLOW THE
INSTRUCTION MANUAL OF THE RESPECTIVE WASHER. FLAT BOTTOM WELLS
ARE USED FOR SERION ELISA CLASSIC. ALL WELLS SHOULD BE FILLED WITH
EQUAL VOLUMES OF WASHING BUFFER. AT THE END OF THE PROCEDURE
ENSURE THAT THE WELLS ARE FREE OF ALL WASHING BUFFER BY TAPPING
THE INVERTED MICROTEST PLATE ON A PAPER TOWEL. AVOID FOAM! DO NOT
SCRATCH COATED WELLS DURING WASHING AND ASPIRATION. IF USING AN
AUTOMATED WASHER, ENSURE IT IS OPERATING CORRECTLY.
7.2 Sample preparation and storage

LIPAEMIC, HEMOLYTIC OR ICTERIC SAMPLES SHOULD ONLY BE TESTED
WITH RESERVATIONS ALTHOUGH IN OUR TESTING NO NEGATIVE INFLUENCE
HAS BEEN FOUND. OBVIOUSLY CONTAMINATED SAMPLES (SERUM OR
PLASMA) SHOULD NOT BE TESTED DUE TO THE RISK OF WRONG RESULTS.
SERUM OR PLASMA (EDTA, CITRATE, HEPARIN) COLLECTED ACCORDING TO
STANDARD LABORATORY METHODS ARE SUITABLE SAMPLES.
Samples must not be thermally inactivated.

7.2.1 Sample preparation

BEFORE RUNNING THE TEST, SAMPLES MUST BE DILUTED IN DILUTION BUFFER
(V1 + V2) AS FOLLOWS:
SERION ELISA classic Leptospira IgG
V1 + V2 = 1+100

sample

43

AFTER DILUTION AND BEFORE PIPETTING INTO THE MICROTITER PLATE THE
SAMPLES MUST BE MIXED THOROUGHLY TO PREPARE A HOMOGENOUS
SOLUTION.
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SERION ELISA classic Leptospira IgM

RHEUMATOID FACTOR-INTERFERENCE:
RHEUMATOID FACTORS ARE AUTOANTIBODIES MAINLY OF THE IGMCLASS, WHICH PREFERABLY BIND TO IGG-IMMUNE-COMPLEXES. THE
PRESENCE OF NON-SPECIFIC IGM-ANTIBODIES (RHEUMATOID FACTORS) CAN
LEAD TO FALSE-POSITIVE RESULTS IN THE IGM-ASSAY. FURTHERMORE,
THE POSSIBILITY EXISTS, THAT WEAK-BINDING PATHOGEN-SPECIFIC IGMANTIBODIES ARE DISPLACED BY STRONGER-BINDING IGG-ANTIBODIES. IN
THIS CASE, IGM-DETECTION CAN LEAD TO FALSE-NEGATIVE RESULTS.
THEREFORE IT IS NECESSARY TO PRETREAT SAMPLES WITH RHEUMATOID
FACTOR-ABSORBENS PRIOR TO IGM DETECTION (SERION RHEUMATOID
FACTOR-ABSORBENT Z200 (20 ML/100 TESTS)).
BEFORE RUNNING THE TEST, RHEUMATOID FACTOR-ABSORBENT (V1) MUST BE
DILUTED 1+4 IN DILUTION BUFFER (V2).
V1 + V2 = 1 + 4

Rf-absorbent

SAMPLES (V4) MUST BE DILUTED IN THIS RF-DILUTION BUFFER (V3)
V4 + V3 = 1+100

sample

7.2.2 Sample storage

THE STOPPERED SAMPLES CAN BE STORED IN A REFRIGERATOR UP TO 7 DAYS
AT 2-8°C. EXTENDED STORAGE IS POSSIBLE AT  -20°C.
AVOID REPEATED FREEZING AND THAWING OF SAMPLES.
Diluted samples can be stored at 2-8°C for one week.
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7.3. Preparation of kit reagents
7.3.1 Microtest strips

MICROTEST STRIPS IN FRAME ARE PACKED WITH DESICCANT IN AN
ALUMINUM BAG. TAKE UNREQUIRED CAVITIES OUT OF THE FRAME AND
PUT THEM BACK INTO THE PRESS-SEAL BAG. CLOSE PRESS-SEAL BAG
CAREFULLY TO ENSURE AIRTIGHT CONDITIONS.
7.3.2 Control sera / standard sera

CONTROL AND STANDARD SERA ARE READY-TO-USE AND MUST NOT BE
DILUTED ANY FURTHER. THEY CAN BE USED DIRECTLY FOR THE TEST
RUN.
FOR EACH TEST RUN AND FOR EACH TEST SYSTEM - INDEPENDENT OF
THE NUMBER OF MICROTEST STRIPS TO BE USED - CONTROL AND
STANDARD SERA MUST BE INCLUDED. THE CUT-OFF-CONTROL SHOULD
BE SET UP IN DUPLICATE. WITH THE QUANTITATIVE TESTS THE
STANDARD SERUM SHOULD ALSO BE SET UP IN DUPLICATE.
DO NOT TREAT CONTROL SERA WITH RF-ABSORBENT.
7.3.3 Anti-human-IgG-, IgM- or IgA-AP-conjugate (ready-to-use)

PLEASE DO NOT MIX UP CONJUGATES FROM DIFFERENT KITS. THEY ARE
OPTIMIZED FOR EACH LOT. CONJUGATES ARE EXCHANGEABLE AS
DESCRIBED IN 7.1.
AVOID CONTAMINATION OF READY-TO-USE CONJUGATES (PLEASE POUR
SUFFICIENT FOR TEST INTO A SECONDARY CONTAINER TO AVOID
REPEATEDLY PIPETTING FROM THE ORIGINAL BOTTLE).
7.3.4 Washing solution

DILUTE WASHING BUFFER CONCENTRATE (V1) 1:30 WITH DISTILLED
WATER TO A FINAL VOLUME OF V2.
EXAMPLE:

buffer concentrate (V1)
33.3 ml
1 ml

final volume (V2)
1000 ml
30 ml

7.3.5 Dilution buffer for samples (ready-to-use)
7.3.6 Substrate (ready-to-use)

TO AVOID CONTAMINATION USE GLOVES. FOR PIPETTING SUBSTRATE
SOLUTION USE STERILE TIPS ONLY!
7.3.7 Stopping solution (ready-to-use)
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7.4. Overview - test procedure
Leptospira IgG/IgM
quantitative

IN CASE OF IGM-DETECTION ABSORPTION OF
RHEUMATOID FACTOR! SAMPLE DILUTION
1 + 100

PIPETTE DILUTED SAMPLES AND READY-TOUSE CONTROL SERA / STANDARD SERA INTO
THE MICROTEST WELLS (100 µL)

INCUBATION 60
MIN./37°C
MOIST CHAMBER
WASH
PIPETTE CONJUGATE SOLUTION (100 µL)

INCUBATION 30
MIN./37°C
MOIST CHAMBER
WASH
PIPETTE SUBSTRATE SOLUTION (100 µL)

INCUBATION 30
MIN./37°C
MOIST CHAMBER
PIPETTE STOPPING SOLUTION (100 µL)

READ EXTINCTION AT 405 NM
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7.5 Test procedure
1.

Place the required number of cavities in the frame and prepare a protocol sheet.

2.

Add each 100 µl of diluted sample or ready-to-use controls into the appropriate wells of
microtest strips. Spare one well for substrate blank, e.g.:
IgG/IgM quantitative
well A1
well B1
well C1
well D1
well E1

substrate blank
negative control
standard serum
standard serum
sample 1....

3.

Sample incubation for 60 minutes (+/- 5 min) at 37°C (+/- 1°C) in moist chamber

4.

After incubation wash all wells with washing solution (by automated washer or manually):
- aspirate or shake out the incubation solution
- fill each well with 300 µl washing solution
- aspirate or shake out the washing buffer
- repeat the washing procedure 3 times (altogether 4 times!)
- dry by tapping the microtest plate on a paper towel

5.

Addition of conjugate
ADD 100 µL OF IGG-/IGM-/IGA-CONJUGATE (READY-TO-USE) TO THE
APPROPRIATE WELL (EXCEPT SUBSTRATE BLANK)

6.

Conjugate incubation for 30 minutes (+/- 1 min) * at 37°C (+/- 1°C) in moist chamber.

7.

After incubation wash all wells with washing solution (see above)

8.

Addition of substrate
ADD 100 µL SUBSTRATE SOLUTION (READY-TO-USE) TO EACH WELL
(INCLUDING WELL FOR SUBSTRATE BLANK!)

9.

Substrate incubation for 30 minutes (+/- 1 min) * at 37°C (+/- 1°C) in moist chamber.

10. Stopping of the reaction

ADD 100 µL STOPPING SOLUTION TO EACH WELL, SHAKE MICROTEST PLATE
GENTLY TO MIX.
11. Read optical density

READ OD WITHIN 60 MINUTES AT 405 NM AGAINST SUBSTRATE BLANK,
REFERENCE WAVE LENGTH BETWEEN 620 NM AND 690 NM (E.G. 650 NM).
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*

Please note, that under special working-conditions internal laboratory adaptations of the incubation times
could be necessary.
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8. TEST EVALUATION
SERION ELISA classic Leptospira IgG/IgM (quantitative)
8.1 Single-point quantification with the 4PL method

OPTIMIZED ASSIGNMENT OF EXTINCTION SIGNALS TO QUANTITATIVE
VALUES IS GUARANTEED BY USING NON-LINEAR FUNCTIONS, WHICH
ADJUST A SIGMOIDE CURVE WITHOUT ANY FURTHER TRANSFORMATION TO
OD-VALUES.
Determination of antibody concentrations with the SERION ELISA classic is carried out by the
logistic-log-model (4 PL; 4 parameter) which is ideal for exact curve-fitting. It is based on the
formula:

1 + e B(C - In conc.)

THE PARAMETERS A, B, C, AND D ARE REPRESENTATIVE FOR THE EXACT SHAPE
OF THE CURVE:
1. lower asymptote
2. slope of the curve
3. turning point
4. upper asymptote

¢
¢
¢
¢

parameter A
parameter B
parameter C
parameter D

FOR EACH LOT THE STANDARD CURVE IS EVALUATED BY INSTITUT
VIRION\SERION GMBH (WÜRZBURG, GERMANY) IN SEVERAL REPEATED TEST
RUNS UNDER OPTIMAL CONDITIONS. TIME CONSUMING AND COST
INTENSIVE CONSTRUCTION OF THE STANDARD CURVE BY THE USER IS NOT
NECESSARY.
FOR EVALUATION OF ANTIBODY CONCENTRATIONS A LOT SPECIFIC
STANDARD CURVE AS WELL AS A LOT SPECIFIC EVALUATION TABLE IS
INCLUDED WITH EACH TEST KIT. APPROPRIATE EVALUATION SOFTWARE IS
AVAILABLE ON REQUEST.
TO COMPENSATE FOR NORMAL TEST VARIATIONS AND ALSO FOR TEST RUN
CONTROL A STANDARD SERUM IS USED IN EACH INDIVIDUAL TEST RUN. FOR
THIS CONTROL SERUM A ‘’REFERENCE VALUE’’ WITH A VALIDITY RANGE IS
DETERMINED BY THE QUALITY CONTROL OF THE PRODUCER. WITHIN THIS
RANGE A CORRECT QUANTIFICATION OF ANTIBODY CONCENTRATION IS
ENSURED. SINCE THE STANDARD SERUM IS NOT NECESSARILY A POSITIVE
CONTROL, THE VALUE OF THE STANDARD SERUM MAY BE BORDERLINE OR
NEGATIVE IN SOME ELISA TESTS.
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8.2 Criteria of validity
-

the substrate blank must be OD < 0.25

-

the negative control must be negative

-

quantitative ELISA: the mean OD-value of the standard serum must be within the validity range,
which is given on the lot specific quality control certificate of the kit (after subtraction of the
substrate blank!)

-

qualitative ELISA: the mean OD-value of the positive control must be within the validity range,
which is given on the lot specific quality control certificate of the kit (after subtraction of the
substrate blank!)

-

the variation of OD-values may not be higher than 20%.

IF THESE CRITERIA ARE NOT MET, THE TEST IS NOT VALID AND MUST BE
REPEATED.
8.3 Calculation
SERION ELISA classic Leptospira IgG/IgM (quantitative)
8.3.1 Non-automated evaluation

FOR THE TEST EVALUATION A STANDARD CURVE AND AN EVALUATION
TABLE ARE INCLUDED IN THE TEST KIT SO THAT THE OBTAINED OD-VALUES
MAY BE ASSIGNED TO THE CORRESPONDING ANTIBODY ACTIVITY. THE
REFERENCE VALUE AND THE VALIDITY RANGE OF THE STANDARD SERUM IS
GIVEN ON THE EVALUATION TABLE (QUALITY CONTROL CERTIFICATE).
The blank (A1) must be subtracted from all OD-values prior to the evaluation.

Method 1: Qualitative Evaluation

TO FIX THE CUT-OFF RANGES PLEASE MULTIPLY THE MEAN VALUE OF THE
MEASURED STANDARD-OD WITH THE NUMERICAL DATA OF THE
CERTIFICATE OF QUALITY CONTROL (SEE SPECIAL CASE FORMULAS), E.G.:
OD = 0.502 X MW (STD) WITH UPPER
CUT-OFF OD = 0.352 X MW (STD)
WITH LOWER CUT-OFF
IF THE MEASURED MEAN ABSORBANCE VALUE OF THE STANDARD SERUM
IS 0.64, THE RANGE OF THE CUT- OFF IS IN BETWEEN 0.225-0.321.

METHOD 2: CONTINUOUS DETERMINATION OF ANTIBODY ACTIVITIES USING
THE STANDARD CURVE.
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SO CALLED INTERASSAY VARIATIONS (DAY TO DAY DEVIATIONS AND
LABORATORY TO LABORATORY DEVIATIONS) ARE COMPENSATED BY
MULTIPLICATION OF THE CURRENT MEASURED VALUE OBTAINED WITH A

SAMPLE WITH THE CORRECTION FACTOR F. THIS FACTOR IS CALCULATED
AS FOLLOWS:
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THE PROCEDURE IS NECESSARY TO ADJUST THE CURRENT LEVEL OF THE TEST
OF THE USER WITH THE LOT- SPECIFIC STANDARD CURVE.
FIRST, DAILY DEVIATIONS HAVE TO BE CORRECTED BY CALCULATING A
FACTOR (CORRECTION FACTOR F):
1.

The mean of the two OD-values of the standard serum has to be calculated and checked that it is
within the given validity range.

2.

Calculation of the factor “F”: the given reference value is divided by the mean of the
extinction of the standard serum:

F = REFERENCE VALUE EXTINCTION STANDARD SERUM / MEAN VALUE
EXTINCTION STANDARD SERUM.
3.

All measured values of samples are multiplied by “F”.

4.

Antibody activities in IU/ml or U/ml can be determined from the standard curve with the
corrected values.

8.3.2

Automatic test evaluation with
SERION easy base 4PL-Software/SERION evaluate-Software

AFTER INPUT OF THE 4 PARAMETERS AND THE REFERENCE VALUE OF THE
STANDARD SERUM, ANTIBODY ACTIVITIES ARE CALCULATED ONLINE. IF
THE OPTICAL DENSITY OF THE STANDARD IS OUT OF THE VALID RANGE, THE
FOLLOWING MESSAGE WILL APPEAR:
SERION easy base 4PL-Software:

”Standards are not in tolerance range” and/or “Distance between standards is greater
than 20 %.”
SERION evaluate-Software:

“Standard values out of ranges in following groups: Group 1-24. Standard value
differ more than 20% in following groups: Group 1-24.”
IN THESE CASES THE TEST RUN IS INVALID AND SHOULD BE REPEATED.
PARAMETERS AND REFERENCE VALUE NEED TO BE CHANGED ONLY IF
THERE IS A CHANGE OF LOT (EVALUATION TABLE SHOWS PARAMETERS
AND REFERENCE VALUES). CORRECT INPUT OF THE LOT SPECIFIC DATA CAN
BE CHECKED ON THE BASIS OF THE IU/ML OR U/ML ASSIGNED TO THE
STANDARD SERUM. THE CALCULATED MEAN VALUE OF THE UNITS HAS TO
CORRESPOND TO THE UNIT VALUE INDICATED ON THE LOT SPECIFIC
CERTIFICATE. THERE IS AN AUTOMATIC CORRECTION OF THE MEASURED
VALUES. IN THE STANDARD VERSION THE PRINTOUT DISPLAYS THE
FOLLOWING:
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SAMPLE
CODE ODVALUE
IU/ML OR
U/ML
EVALUATIO
N
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9. STATEMENTS OF WARNING
9.1 Statements of warning

THE SERION ELISA CLASSIC IS ONLY DESIGNED FOR QUALIFIED PERSONNEL
WHO ARE FAMILIAR WITH GOOD LABORATORY PRACTICE.
ALL KIT REAGENTS AND HUMAN SPECIMEN SHOULD BE HANDLED
CAREFULLY, USING ESTABLISHED GOOD LABORATORY PRACTICE.
-

This kit contains human blood components. Although all control- and cut-off-sera have been
tested and found negative for HBs-Ag-, HCV- and HIV-antibodies, they should be considered
potentially infectious.

-

Do not pipette by mouth.

-

Do not smoke, eat or drink in areas in which specimen or kit reagents are handled.

-

Wear disposable gloves, laboratory coat and safety glasses while handling kit reagents or
specimen. Wash hands thoroughly afterwards.

-

Samples and other potentially infectious material should be decontaminated after the test run.

-

Reagents should be stored safely and be unaccessible to unauthorized access e.g. children.

-

Stopping solution: corrosive (C); cause acid burn (R34)

USE SAFETY GLASSES, GLOVES AND LABORATORY COAT WHILE
HANDLING!
9.2 Disposal

PLEASE OBSERVE THE RELEVANT STATUTORY REQUIREMENTS!
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Appendix III: BCM Letter of Support

27 August 2018

RE:

Nicole Delgado
MPH Student Thesis Project: HSC-SPH-18-0688
“INVESTIGATION OF HANTAVIRUS AND LEPTOSPIROSIS AS POSSIBLE CONTRIBUTING
CAUSES OF UNEXPLAINED KIDNEY DISEASE EPIDEMIC IN NICARAGUA”
Reference number: 176220

Dear Committee for the Protection of Human Subjects,
Please accept this letter of support for the thesis work proposed at Baylor College of Medicine by Nicole
Delgado. I am the Principal Investigator and Dr. Rebecca Fischer is the thesis Advisor here in our
department. Ms. Delgado’s work will be of great public health importance and contribute to our
overarching investigation into the cause of a mysterious disease causing a major public health crisis in
Latin America. Please do not hesitate to contact Dr. Fischer directly at rebecca.fischer@bcm.edu if
anything further is needed on our end.
Sincerely,

Kristy O. Murray, DVM, PhD

Rebecca S.B. Fischer, MPH, PhD
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Appendix IV: BCM IRB Approval Letter
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Appendix V: IRB UTHealth CPHS Approval
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Appendix VI: Variable Description Table
Variable Name
sex
agecat1
agecat2
agecat3
agecat4
city
resid_chichi
drug
drugs
drug_ever
wk_isa_yrs
wk_isa_cat0
wk_isa_cat1
wk_isa_cat3
wk_isa_cat4
wk_isa_cat5
wk_Campo_cat1
wk_Campo_cat0
wk_Campo_cat4
wk_Campo_cat5
occup_acarreo
occup_cosecha
occup_camaron
occup_plagas
occup_horno
occup_maleza
occup_quema
occup_corte_m
occup_siembra
occup_riego
occup_rymma
occup_fabrica
worksoil
Campoworker
worksoil_road
worksoil_ditch
worksoil_aero
worksoil_dry
worksoil_wet
worksoil_Campo
worksoil_other
Variable Name
rats_Casa
rats_Casa_feces

Variable Label
Participant Sex
Age is 30+ (years)
Participant Age
Age is 25+ (years)
Age is 35+ (years)
City of Residence
Lived in Chichigalpa
Drug Use
Drugs
Drug Use (Current/Former)
Total years worked at ISA
Total years worked at ISA (categorical)
Total years worked at ISA (<5)
Total years worked at ISA
Total years worked at ISA >2 yrs
Total years worked at ISA >10 yrs
Total years in Cane Fields (>5)
Total years in Cane Fields (categorical)
Total years worked at Field > 2 yrs
Total years worked at Field >10yrs
Works in Paqueta/Carry
Works in Harvest (operario general)
Works in Camaronera
Works in Control de Pest
Works in Oven
Works in Control de Weeds
Works in Burn (Field/Oven)
Works in Cut Sugar Cain - Mechanized
Works in occup_Planting/Reseeding
Works in Irrigation/Drainage
Automechanic
Works in Factory
works with soil
Works in field (either soil and/or water)
Type of Working Soil - Road
Type of Working Soil - Ditch
Type of Working Soil - Aerosolizado
Type of Working Soil - Dry
Type of Working Soil - Wet
Type of Working Soil - Field
Type of Working Soil or Other_Spec
Variable Label
Ever sees Rodents in Home
Ever sees Rodent Feces in Home 61

rats_Casa_daily
rats_Casa_freq
rats_Casa_freq2
handwash_Casa
handwash_foun
handwash_ditch
handwash_drain
handwash_well
handwash_truck
handwash_other
handwash_always
handwash_usualy
handwash_rarely
handwash_never
handwash_cat
drink_etoh_freq
drink_etoh_otro
drink_etoh_ot
drink_etoh_ce
drink_bottle
drink_fountain
drink_truck
drink_well
drink_ditch
drink_drain
drink_drain ditch
wellwater_drink
ppe_gloves
ppe_gloves_yn
ppe_glasses
ppe_glasses_yn
ppe_mask
ppe_mask_yn
ppe_nose
ppe_nose_yn
ppe_pants
ppe_pants_yn

Sees Rodents in Home Daily
Sees Rodents in Home, Frequency
Sees Rodents in Home, Frequency
Handwash agudo Water from My House
Handwash agudo Fountain
Handwash agudo Drain
Handwash agudo Drainage Tube
Handwash Well
Handwash Truck
Handwash Other
Handwash Always
Handwash Usually
Handwash Rarely
Handwash Never
Handwash Catagorical
Drink etoh Frequently
drink_etoh_Other
drink_etoh_Other1
drink_etoh_
Drink from Bottle
in the field drinks water from fountain
in the field drinks water from ISA
drink_truck
in the field drinks water from a drink_well
in the field drinks water from the irrigation
ditch
in the field drinks water from
drink_drainage pipe
drinks water from the ditch or drainage
tube
Drinks Well Water at Home or Work
Used Gloves - Always/Occasionally/Never
Used Gloves - Yes/No
Used Protective Glasses
Used Protective Glasses - Yes/No
Used Mask
Used Mask - Yes/No
Used Protective Nose Covering
Used Protective Nose Covering - Yes/No
Used Long Pants
Used Long Pants - Yes/No
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Appendix VII: Previous Study Acute Case Interview Form
Acute Case Date
SECTION 1: Acute Case
(from Case Report, Form A):
I'm going to ask you about what happened when you were sick on:
_____/_____/________
How long were you sick before going to the hospital?
□ the same day □____ days
□____weeks
□I Don’t Know
What time did your symptoms start? _____:______
□Morning
□Afternoon
□Night
□I Don’t
Know
Were you working at the time you got sick?
□Yes
□ No □I Don’t Know
If you answer is Yes
What job were you currently working when you got sick? ____________________________
How many hours of the day had you been working when your symptoms began? ______
Did you feel very hot immediately when your symptoms began?
□Yes
□ No □I Don’t Know
Please tell me if you had any of these symptoms during your illness (this episode, including the week before):
Symptoms during the acute disease
Description or notes
Fever
□Yes
□No
□I Don’t Know
Temp: ____. __ °C, duration: ___days
Headache
□Yes
□No
□I Don’t Know
Abdominal pain
□Yes
□No
□I Don’t Know
Low back pain/Back pain
□Yes
□No
□I Don’t Know
Cervicalgia/Neck pain
□Yes
□No
□I Don’t Know
Arthralgia
□Yes
□No
□I Don’t Know
Which joint:
Myalgia
□Yes
□No
□I Don’t Know
Chest pain
□Yes
□No
□I Don’t Know
Nausea
□Yes
□No
□I Don’t Know
Vomiting
□Yes
□No
□I Don’t Know
Diarrhea
□Yes
□No
□I Don’t Know
Muscle weakness
□Yes
□No
□I Don’t Know
Cold/Chills
□Yes
□No
□I Don’t Know
Cough
□Yes
□No
□I Don’t Know
Dyspnea/Difficulty breathing
□Yes
□No
□I Don’t Know
Fatigue/Discomfort
□Yes
□No
□I Don’t Know
Jaundice
□Yes
□No
□I Don’t Know
Tremors
□Yes
□No
□I Don’t Know
Rash
□Yes
□No
□I Don’t Know
Where:
Difficulty or Pain with Urination
□Yes
□No
□I Don’t Know
Blurry vision
□Yes
□No
□I Don’t Know
Edema/Swelling
□Yes
□No
□I Don’t Know
Where:
Cramps
□Yes
□No
□I Don’t Know
Paresthesia (ex. Burning/Prickling)
□Yes
□No
□I Don’t Know
Dizziness
□Yes
□No
□I Don’t Know
Confusion
□Yes
□No
□I Don’t Know
Red eyes
□Yes
□No
□I Don’t Know
Other symptoms:
□______ night(s)
□I Don’t Know
□____ days
□____ weeks
□ I Don’t Know
Acute Case Date (from Form A):
Occupation
I want to know about the job you were working on:
_____/_____/________
What was your job/occupation?
□ Hauler/loader
□ General Crop Operator
□ Shrimp farm worker
□ Fertilizer Operator
□ Pest control
□ Oven Operator
□ Weed control
□ Sugarcane burning
□ Sugarcane cutting, mechanical
□ Sowing/Reseeding
□ Sugarcane cutting, manual
□ Irrigation/Drainage
□ Seed cutting
□ Auto mechanic
□ Factory
□ Other: ____________________________
How many nights did you spend in the hospital?
How long did the symptoms last (in total)?
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What is the schedule that you normally worked?
□ 6am □ 7am
□ 8am
□ 9am
□ 10am
□ 11am
□ 12md □ 1pm □ 2pm □ 3pm □ 4pm □ 5pm
□ 6pm □ 7pm
□ 8pm
□ 9pm
□ 10pm
□ 11pm
□ 12mn □ 1am □ 2am □ 3am □ 4am □ 5am
If you work shift, the second shift:
□ 6am □ 7am
□ 8am
□ 9am
□ 10am
□ 11am
□ 12md □ 1pm □ 2pm □ 3pm □ 4pm □ 5pm
□ 6pm □ 7pm
□ 8pm
□ 9pm
□ 10pm
□ 11pm
□ 12mn □ 1am □ 2am □ 3am □ 4am □ 5am
How many days a week? □ ≤3 days □ 4 days
□ 5 days
□ 6 days
□ 7 days
□ other ____________
Which months did you work during this season?
□ Jan

□ Feb

□ Mar

□ April

□ May

□ Jun

□ Jul

□ Aug

□ Sep

□ Oct

□ Nov

□ Dec

When did you start working this season? _____/_____/________
What other work were you doing during the 3 weeks before you got sick?
□ Only the same as above
□ Other: _________________________________________________________________________
Did your work imply that you are working on water contact (standing or digging in water)? □Yes □No □I Don’t Know
If your answer is Yes: What type of water? (Check all that apply)
□Irrigation
□Drainage
□Water source
□Rain
□Wet floor
□Standing water
□Shrimp water
□Other: ____________________
Did your work imply that you are working in contact with soil? (ex. contact with skin or respiration) □Yes □No □I Don’t Know
If your answer is Yes: What type of soil? (Check all that apply)
□Dry soil
□Wet soil
□Field soil
□Drainage soil
□Aerosolized soil
□Ground on the Road
□Other: ____________________
Did your work imply that you are working in contact with the burned cane? □Yes □No □I Don’t Know
If your answer is Yes: What type of contact? (Check all that apply)
□Burning the sugar cane
□ Pick up the burnt cane
□Oven work
□Loading the burned sugar cane
□Other: ____________________

Does your work imply that you are working in contact with chemicals? □Yes □No □I Don’t Know
If your answer is Yes: What type of chemicals? (Check all that apply)
□pesticide
□herbicide
□fertilizer
□factory chemical(s) □Other:__________________
Do you know specifically which chemical(s)? __________________________________________________
What type of contact? (Check all that apply)
□Application
□Fabric
□Skin contact □Ingestion □Dust/Inhalation
□Contact with eyes □Other: ____________________
Where did you get drinking water in the field? (Check all that apply)
□Water from home
□Fountain
□Irrigation
□Drainage tube
□Water well
□Water truck
□Bottled water □Other: ______________________________________
If you answer is Water from home: What water do you drink if you have finished the water you brought?
_____________________________________________________
Do you wash your hands before you eat in the field?
□Yes, Always
□Usually
□Rarely
□Other ________ □ No, Never □I Don’t Know
If your answer is Yes: Where do you wash your hands? (Check all that apply)
□Water from home
□Fountain
□Irrigation
□Drainage tube
□Water well
□Water truck
□Bottled water
□Other: ______________________________________
Which of the following do you use when you are working?
Gloves
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Glasses or sunglasses
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Mouth cover (mask)
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Nose cap
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Long pants
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Long sleeved shirt
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Boots
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Waterproof boots
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Hat or cap
□Yes, Always
□Usually
□Rarely □ No, Never
□I Don’t Know
Did you work any other job(s) at the time? (ex. mani, plantains, extraction or others jobs) □Yes
If your answer is Yes: Describe the other job(s) _______________________
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□No

□I Don’t Know

Have you ever seen rats while working?
□Yes
□No
□I Don’t Know
Have you ever had the heat stress while working? □Yes
□No
□I Don’t Know
If your answer is Yes:
Have you ever had to stop working because you had the heat stress? □Yes
□No
□I Don’t Know
Have you ever had dehydration while working? □Yes
□No
□I Don’t Know
If your answer is Yes:
Have you ever had to stop working because of dehydration?
□Yes
□No
□I Don’t Know
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SECTION 2:
Are you accustomed to taking pills or medications, for example, when you have a pain or a fever? Please think about all the
prescriptions, self-treatment, natural treatments that you normally use.
□Yes □No □I Don’t Know
Please tell me if you have ever taken any of the following medications.
(Ask about all)
How often do you have an episode while taking these
How many days do
pain pills?
you take during
each occurrence?
□antibiotic
□every: ____days
____weeks ____months
□less than 1/year
□never
□amoxicillin
□ciprofloxacin
□gentamicin
□penicillin
□trimethoprim
□acetaminophen/
paracetamol
□ibuprofen
□naproxen
□metamizole
□diclofenac
□diclofenac gel
□ranitidine
(zantac)
□omeprazole
(Prilosec)
□
□

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never

□every: ____days
□less than 1/year

____weeks

____months
□never
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How much time has
passed since the last
time you took pills?

Which one did you use in the week before you became sick (the acute case date)? (Check all that apply)
□None
□antibiotic □acetaminophen/paracetamol
□ibuprofen
□omeprazole (Prilosec)
□ranitidine (zantac)
□ Other_____________________ □I Don’t Know
Which type do you use to treat your symptoms/disease during the occurrence? (Check all that apply)
□None
□antibiotic □acetaminophen/paracetamol
□ibuprofen
□omeprazole (Prilosec)
□ranitidine (zantac)
□ Other_____________________ □I Don’t Know
Has there been a time a doctor told you that you have elevated creatine or any kidney problem? □Yes
If the answer is Yes: When? _____________________________ (Age, Date, or Time since then)

□No

□I Don’t Know

Has a doctor ever told you that you have… (Please ask about all)
When?
(Date or age)

Health condition
Asthma
Anemia
Diabetes
Gout
Heart disease
Hepatitis
Hepatic disease
Hypertension
Kidney stones
Cystitis
Other problem/renal disease
Sexually transmitted disease
Frequent urinary tract infections (UTIs)
Pancreatitis
Azotemia
Leptospirosis
Malaria
Chagas
Dengue
Chikungunya
Zika

□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know
□Yes
Know

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□No

□I Don’t

□ Other health condition
□ Other health condition
Have any of your parents or grandparents have…
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Description and notes

Health condition

Who?

Diabetes
□Yes
□No
□I Don’t Know
Gout
□Yes
□No
□I Don’t Know
Heart disease
□Yes
□No
□I Don’t Know
Hepatic disease
□Yes
□No
□I Don’t Know
Hypertension/High blood pressure
□Yes
□No
□I Don’t Know
Kidney stones
□Yes
□No
□I Don’t Know
Cystitis
□Yes
□No
□I Don’t Know
Other problem/kidney disease
□Yes
□No
□I Don’t Know
Frequent urinary tract infections (UTIs)
□Yes
□No
□I Don’t Know
Pancreatitis
□Yes
□No
□I Don’t Know
Azotemia
□Yes
□No
□I Don’t Know
Do you smoke or have smoked at any time in your life?
□ Yes
□ Yes, but only in the past
□ No, never
□ I don’t know
Did you drink or have you drank alcohol?
□ Yes
□ Yes, but only in the past
□ No, never
□ I don’t know
Did you take or have you taken Lija?
□ Yes
□ Yes, but only in the past
□ No, never
□ I don’t know
Did you take or have you taken drugs?
□ Yes → What class?_____________________________________________________
How often?
□ Daily □ 3-4/week
□ 1-2/week
□ 1-2/month
□ Rarely
□Other:____________
□ Yes, but only in the past → What class?________________________________________
□ No, never
□ I don’t know
Do you use or have you used traditional medicine?
□ Yes → Which?
□ Red radish
□ Green radish
□ Basil
□ Noni
□ Horse tail □ Malago □Chamomile □ Other(s): _____________________
How often?
□ Daily □ 3-4/week
□ 1-2/week
□ 1-2/moth
□ Rarely
□Other: ____________
□ Yes, but only in the past → Which?
□Red radish
□ Green radish
□ Basil
□ Noni
□ Horse tail □ Malago □ Chamomile □ Other: _____________________
□ No, never
□ I don’t know
Have you ever been bitten by any insects, rats, or other animal?

□Yes

□No

□I Don’t Know

If the answer is Yes: Which ones? (Check all that apply)
□ Mosquitoes
□ Rat

□ Dog

□ Scorpion
□ Cat

□ Spider

□Snake

□ Other_______________________________
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SECTION 3: Subjective Case
Acute Case Date
In the past, have you ever thought the it is the same type of disease before the episode of
(from Case Report, Form
□Yes □No □I Don’t Know
A): _____/_____/________
*If the answer = “No” or if the date is within two weeks of the Acute Case Date→ MOVE on to SECTION 4*
When was the first time it started? What day?
or ¿How long ago did it start?
“Subjetive Date”:
________________
If the Date is less than a week before the Acute Case _______/________/_____________
Date → MOVE on to SECTION 4*
Please tell me if you had any of the following symptoms during your disease in that moment:
Symptoms during the acute disease
Description or notes
Fever
□Yes
□No
□I Don’t Know
Temp: ____. __ °C, duration: ___days
Headache
□Yes
□No
□I Don’t Know
Abdominal pain
□Yes
□No
□I Don’t Know
Low back pain/Back pain
□Yes
□No
□I Don’t Know
Cervicalgia/Neck pain
□Yes
□No
□I Don’t Know
Arthralgia
□Yes
□No
□I Don’t Know
Which joint:
Myalgia
□Yes
□No
□I Don’t Know
Chest pain
□Yes
□No
□I Don’t Know
Nausea
□Yes
□No
□I Don’t Know
Vomiting
□Yes
□No
□I Don’t Know
Diarrhea
□Yes
□No
□I Don’t Know
Muscle weakness
□Yes
□No
□I Don’t Know
Cold/Chills
□Yes
□No
□I Don’t Know
Cough
□Yes
□No
□I Don’t Know
Dyspnea/Difficulty breathing
□Yes
□No
□I Don’t Know
Fatigue/Discomfort
□Yes
□No
□I Don’t Know
Jaundice
□Yes
□No
□I Don’t Know
Tremors
□Yes
□No
□I Don’t Know
Rash
□Yes
□No
□I Don’t Know
Where:
Difficulty or Pain with Urination
□Yes
□No
□I Don’t Know
Blurry vision
□Yes
□No
□I Don’t Know
Edema/Swelling
□Yes
□No
□I Don’t Know
Where:
Cramps
□Yes
□No
□I Don’t Know
Paresthesia (ex. Burning/Prickling)
□Yes
□No
□I Don’t Know
Dizziness
□Yes
□No
□I Don’t Know
Confusion
□Yes
□No
□I Don’t Know
Red eyes
□Yes
□No
□I Don’t Know
Other symptoms:

69

?

Occupation
What is your current job/occupation at ISA?
□ The same as above → MOVE TO SECTION 4*
□ Hauler/loader
□ Shrimp farm worker
□ Pest control
□ Weed control
□ Sugarcane cutting, mechanical
□ Sugarcane cutting, manual
□ Seed cutting
□ Factory
What is the schedule that you normally worked?

□ General Crop Operator
□ Fertilizer Operator
□ Oven Operator
□ Sugarcane burning
□ Sowing/Reseeding
□ Irrigation/Drainage
□ Auto mechanic
□ Other: ____________________________

□ 6am □ 7am
□ 8am
□ 9am
□ 10am
□ 11am
□ 12md □ 1pm □ 2pm □ 3pm
□ 4pm □ 5pm
□ 6pm □ 7pm
□ 8pm
□ 9pm
□ 10pm
□ 11pm
□ 12mn □ 1am □ 2am □ 3am
□ 4am □ 5am
If you work shift, the second shift:
□ 6am □ 7am
□ 8am
□ 9am
□ 10am
□ 11am
□ 12md □ 1pm □ 2pm □ 3pm
□ 4pm □ 5pm
□ 6pm □ 7pm
□ 8pm
□ 9pm
□ 10pm
□ 11pm
□ 12mn □ 1am □ 2am □ 3am
□ 4am □ 5am
How many days a week? □ ≤3 days □ 4 days
□ 5 days
□ 6 days
□ 7 days
□ other
____________
Which months did you work during this season?
□ Jan
□ Nov

□ Feb

□ Mar

□ April

□ May

□ Jun

□ Jul

□ Aug

□ Sep

□ Oct

□ Dec

Did your work imply that you are working on water contact (standing or digging in water)? □Yes □No □I
Don’t Know
If your answer is Yes: What type of water? (Check all that apply)
□Irrigation
□Drainage
□Water source
□Rain
□Wet floor
□Standing water
□Shrimp water
□Other:
____________________
Did your work imply that you are working in contact with soil? (ex. contact with skin or respiration) □Yes
□No □I Don’t Know
If your answer is Yes: What type of soil? (Check all that apply)
□Dry soil
□Wet soil
□Field soil
□Drainage soil
□Aerosolized
soil
□Ground on the Road
□Other: ____________________
Did your work imply that you are working in contact with the burned cane? □Yes □No □I Don’t Know
If your answer is Yes: What type of contact? (Check all that apply)
□Burning the sugar cane
□ Pick up the burnt cane
□Oven work
□Loading the burned sugar cane
□Other: ____________________

Did your work imply that you are working in contact with chemicals? □Yes
Don’t Know
If your answer is Yes: What type of chemicals? (Check all that apply)

□No

□I

□Pesticide □Herbicide
□Fertilizer
□Factory chemicals
□Other: ______________
Do you know specifically which chemical(s)?
_____________________________________________
What type of contact? (Check all that apply)
□Applied
□Fabric
□Skin contact
□Ingestion
□Inhalation
□Into the eyes
□Other: _____________________
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Which of the following do you use when you are working?
Gloves
□Yes, Always
□Usually
□Rarely
Glasses or sunglasses
□Yes, Always
□Usually
□Rarely
Mouth cover (mask)
□Yes, Always
□Usually
□Rarely
Nose cap
□Yes, Always
□Usually
□Rarely
Long pants
□Yes, Always
□Usually
□Rarely
Long sleeved shirt
□Yes, Always
□Usually
□Rarely
Boots
□Yes, Always
□Usually
□Rarely
Waterproof boots
□Yes, Always
□Usually
□Rarely
Hat or cap
□Yes, Always
□Usually
□Rarely

□ No, Never
□ No, Never
□ No, Never
□ No, Never
□ No, Never
□ No, Never
□ No, Never
□ No, Never
□ No, Never

□I Don’t Know
□I Don’t Know
□I Don’t Know
□I Don’t Know
□I Don’t Know
□I Don’t Know
□I Don’t Know
□I Don’t Know
□I Don’t Know

Are you working any other jobs at the moment? (ex. peanuts, plantains, extraction or other jobs) □Yes
No
□I don’t know
If the answer is Yes: Describe all other jobs _______________________
2. Work History
What have been your other jobs/occupations in your work life?
Activity
Location (Country,
Start Year
Department)
□ Laborer
□ Merchant
□ Farmer
□ Rancher
□ Miner
□ Ship worker
□ Brick manufacturer
□ Technical worker
□ Other(s):

What agricultural activities have you done in your life?
Activity
Location (Country,
Department)
□ Rice
□ Sesame
□ Sugar
□ Peanut
□ Banana
□ Corn
□ Coffee
□ Beans
□ Vegetables
□ Other(s):

What position do you take part in that plant?
Activity
□ Haulage

Start Year
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Start Year

Number of Years

Number of Years

Number of Years

□

□ Shrimp farmer
□ Pest control
□ Weed control
□ Sugar cane cutter, mechanical
□ Sugar cane cutter, manual
□ General Crop Operator
□ Fertilizer Operator
□ Oven Operator
□ Burn the cane
□ Sowing/Reseeding
□ Irrigation/Drainage
□ Auto mechanic
□ Other(s):

SECTION 4:
Do you have any family members, now or in the past, with kidney disease, such as father, mother,
brother, or uncle?
□Yes
□No
□I Don’t Know
Relation
Age when
Sex Occupation
Was it ever in
Did you ever work at ISA?
you became
when you
agriculture?
If the answer is Yes,
sick
became sick
What work and for how long?
□Yes □No □I Don’t
Know
□Yes □No □I Don’t
Know
□Yes □No □I Don’t
Know
□Yes □No □I Don’t
Know
What do you think is causing kidney disease in your community?

□Yes □No □I Don’t Know
□Yes □No □I Don’t Know
□Yes □No □I Don’t Know
□Yes □No □I Don’t Know

What is the last level of the school that you completed?
□Primary →
Grade:_______
□Secondary → Grade:_______
□Superior →
Technical school?
□Yes □No
□I Don’t Know
□University→ Bachelor’s?
□Yes □No □I Don’t
Know
□None
What is your marital status?
□Single

□Married

□In a relationship

□Widowed

□Divorced
□Other: _________________________
Where do you live currently?
Address: ___________________________________________
Neighborhood/Region:___________________
Municipality: ___________________________ Department:___________________________
Do you work in the field/garden/farm where you currently live?
□Yes □No □I Don’t Know
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How is he/she
doing?

(Ex.
death/dialysis

If the answer is Yes: Have you ever seen rats or mice while working there?
Don’t Know

□Yes □No □I

Acute Case Date
¿ Where did you live when you got sick in (from Case Report, Form
?
A): _____/_____/________
□ The same house where I currently live
□ Other house:
If it is a different house:
Address: ___________________________________________
Neighborhood/Region:___________________
Municipality: ___________________________
Department:___________________________
□Rural
□Urban
□Peri-urban
□I don’t know
Did you work in the field/garden/farm where you lived?

□Yes □No □I Don’t Know

If the answer is Yes: Have you ever seen rats or mice while working there?

□Yes

□No □I Don’t Know
*If Subjective Date = Acute Case Date →MOVE on to the END*
“Subjective Date”:
¿Where did you live when you got sick in
?
(from page 4):
□ The same house where I currently live_______/________/______
□ The same house where I lived when I_______
became ill on acute case date (above)
□ Another house:
If the house is different:
Address: ___________________________________________
Neighborhood/Region:___________________
Municipality: ___________________________
Department:___________________________
□Rural
□Urban
□Peri-urban
□ I don’t know
Did you work in the field/garden/farm where you lived?
If the answer is Yes: Have you ever seen rats or mice while working
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□Yes □No □I Don’t Know
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